Skip to main content
. 2018 May 21;2018:6463807. doi: 10.1155/2018/6463807

Figure 6.

Figure 6

Geranylgeraniol (GGOH) does not rescue C2C12 myoblasts from GGTI-286-induced (IC50) compromised cell viability. GGTI-286 was used as a specific inhibitor of protein geranylgeranyltransferases. C2C12 myoblasts were exposed for 24, 72, or 120 h to GGTI-286 (day 1—proliferating myoblasts, day 3—differentiating myotubes, and day 5—differentiated myotubes). GGTI-286 (IC50): day 1—25 μM, day 3—24 μM, and day 5—23 μM or vehicle control (0.1% DMSO or 2% HS DMEM) without or with GGOH. GGOH (10 μM) could not reverse the drop in cell viability induced by GGTI-286. Two-way ANOVA test [time (proliferating myoblasts, differentiating myotubes, differentiated myotubes)] amounted to F(2, 42) = 10.69, p = 0.0002; treatment: GGTI-286, GGOH, and GGTI-286 + GGOH: F(2, 21) = 346.8, p < 0.0001; interaction: F(4, 42) = 18.73, p < 0.0001, followed by Bonferroni's multiple comparisons employed to analyze the data. Error bars = SEM and ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 for comparison between the means. Results are means of three independent experiments.